For the quarter ended December 2025, Axsome Therapeutics (AXSM Quick QuoteAXSM - Free Report) reported revenue of $196 million, up 65% over the same period last year. EPS came in at -$0.71, compared to -$0.96 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $193.01 million, representing a surprise of +1.55%. The company delivered an EPS surprise of -1%, with the consensus EPS estimate being -$0.70.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Axsome performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Product sales, net: $194.7 million versus $191.25 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +66% change.
• Revenues- Royalty revenue and milestone revenue: $1.3 million versus the nine-analyst average estimate of $1.18 million. The reported number represents a year-over-year change of -9.5%.
• Product Sales, net- SYMBRAVO: $4.1 million versus $5.27 million estimated by seven analysts on average.
• Product Sales, net- Auvelity: $155.1 million versus $151.25 million estimated by seven analysts on average.
• Product Sales, net- Sunosi: $36.7 million compared to the $33.86 million average estimate based on seven analysts.

View all Key Company Metrics for Axsome here>>>

Shares of Axsome have returned -1.2% over the past month versus the Zacks S&P 500 composite's +1.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.